Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Shimokawa T, Okamoto H, Machida R, Misumi Y, Hosomi Y, Yoneshima Y, Tanaka H, Okishio K, Simizu J, Goto K, Akamatsu H, Kubota K, Nakagawa K, Horinouchi H, Ando M, Kataoka T, Ohe Y. Shimokawa T, et al. Among authors: okishio k. Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22. Lung Cancer. 2023. PMID: 37156212 Free article. Clinical Trial.
A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer.
Kawaguchi T, Takada M, Ando M, Okishio K, Atagi S, Fujita Y, Tomizawa Y, Hayashihara K, Okano Y, Takahashi F, Saito R, Matsumura A, Tamura A. Kawaguchi T, et al. Among authors: okishio k. Eur J Cancer. 2012 Mar;48(5):672-7. doi: 10.1016/j.ejca.2011.11.020. Epub 2011 Dec 13. Eur J Cancer. 2012. PMID: 22172569 Clinical Trial.
Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
Morimoto M, Okishio K, Akira M, Omachi N, Tamiya A, Asami K, Kawaguchi T, Atagi S. Morimoto M, et al. Among authors: okishio k. Clin Lung Cancer. 2017 Mar;18(2):e117-e127. doi: 10.1016/j.cllc.2016.09.004. Epub 2016 Oct 3. Clin Lung Cancer. 2017. PMID: 28340925 Free article.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R, Okishio K, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, Kanai O, Kumagai T, Kibata K, Tsukamoto H, Oizumi S, Fujimoto D, Tanaka H, Mizuno K, Masuda T, Kozuki T, Haku T, Suzuki H, Okamoto I, Hoshiyama H, Ueda J, Ohe Y. Morita R, et al. Among authors: okishio k. Lung Cancer. 2020 Feb;140:8-18. doi: 10.1016/j.lungcan.2019.11.014. Epub 2019 Nov 20. Lung Cancer. 2020. PMID: 31838169 Free article.
90 results